Molecular Imaging and Radionuclide Therapy最新文献

筛选
英文 中文
Erratum. 勘误表。
IF 0.9
Molecular Imaging and Radionuclide Therapy Pub Date : 2023-10-20 DOI: 10.4274/mirt.galenos.2023.e001
{"title":"Erratum.","authors":"","doi":"10.4274/mirt.galenos.2023.e001","DOIUrl":"10.4274/mirt.galenos.2023.e001","url":null,"abstract":"","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"32 3","pages":"257"},"PeriodicalIF":0.9,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/05/40/MIRT-32-257.PMC10600553.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49692972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term Intense 18F-FDG Uptake by the Homeostatic Matrix-associated Inflammatory Response May Mimic Malignancy Recurrence. 稳态基质相关炎症反应对18F-FDG的长期强烈摄取可能模拟恶性肿瘤复发。
IF 0.9
Molecular Imaging and Radionuclide Therapy Pub Date : 2023-10-20 DOI: 10.4274/mirt.galenos.2023.92499
Fatih Tamer, Bülent Yazıcı, Aylin Oral, Ayşegül Akgün
{"title":"Long-term Intense <sup>18</sup>F-FDG Uptake by the Homeostatic Matrix-associated Inflammatory Response May Mimic Malignancy Recurrence.","authors":"Fatih Tamer,&nbsp;Bülent Yazıcı,&nbsp;Aylin Oral,&nbsp;Ayşegül Akgün","doi":"10.4274/mirt.galenos.2023.92499","DOIUrl":"10.4274/mirt.galenos.2023.92499","url":null,"abstract":"<p><p>A 70-year-old man underwent right upper lobectomy for lung adenocarcinoma. During the operation, hemostatic matrix (as known Floseal<sup>®</sup>) was used to prevent pulmonary laceration-associated bleeding. When <sup>18</sup>F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography was performed for staging after surgery, intense <sup>18</sup>F-FDG uptake was observed in the cicatricial fibrotic tissue in the operation area, and no significant change was observed in that area during the 4-year follow-up. Because it remained stable for several years without treatment, this finding was thought to be due to a foreign body reaction caused by the homeostatic material.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"32 3","pages":"233-236"},"PeriodicalIF":0.9,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/44/a2/MIRT-32-233.PMC10600545.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49692977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Initial Findings on the Use of [225Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors. 使用[225Ac]Ac-DOTATE治疗神经内分泌肿瘤患者的初步发现。
IF 0.9
Molecular Imaging and Radionuclide Therapy Pub Date : 2023-10-20 DOI: 10.4274/mirt.galenos.2023.38258
Emre Demirci, Nalan Alan Selçuk, Gamze Beydağı, Meltem Ocak, Türkay Toklu, Kaan Akçay, Levent Kabasakal
{"title":"Initial Findings on the Use of [<sup>225</sup>Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors.","authors":"Emre Demirci,&nbsp;Nalan Alan Selçuk,&nbsp;Gamze Beydağı,&nbsp;Meltem Ocak,&nbsp;Türkay Toklu,&nbsp;Kaan Akçay,&nbsp;Levent Kabasakal","doi":"10.4274/mirt.galenos.2023.38258","DOIUrl":"10.4274/mirt.galenos.2023.38258","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to evaluate the stability, safety, and efficacy of alpha-targeted therapy with [<sup>225</sup>Ac]Ac-DOTATATE in patients with grade 1/2 metastatic neuroendocrine tumors (NETs).</p><p><strong>Methods: </strong>This retrospective cohort included patients (n=11) with metastatic NETs from different primary sites (bronchial, pancreatic, nonpancreatic gastroenteropancreatic NETs, paraganglioma, and unknown primary site) treated with [<sup>225</sup>Ac]Ac-DOTATATE with a mean activity of 8.2±0.6 MBq (range: 7.5-10.0 MBq) at our institution between November 2019 and March 2022. The <i>in vivo</i> and <i>in vitro</i> stability of [<sup>225</sup>Ac]Ac-DOTATATE was calculated. The safety profile was evaluated according to the CTCAE-v5.0. Treatment efficacy was evaluated according to [<sup>68</sup>Ga] Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) images and the RECIST 1.1 criteria.</p><p><strong>Results: </strong>Patients had 73% (n=8) lymph node metastases, 91% (n=10) liver metastases, 36% (n=4) lung metastases, and 73% (n=8) bone metastases. All but one patient was refractory to treatment with [<sup>177</sup>Lu]Lu-DOTATATE. [<sup>225</sup>Ac]Ac-DOTATATE was stable for at least 5 h in vitro (in saline) and 3 h <i>in vivo</i> (urine and blood samples). Grade 2 renal toxicity and grade 2 hematotoxicity were observed in one patient. No grade 3-4 toxicities were reported. According to post-treatment [<sup>68</sup>Ga]Ga-DOTATATE PET/CT (n=9), 11% (n=1) had progressive disease, 44.4% (n=4) had stable disease, and 44.4% (n=4) had a partial response. The disease control rate was 89% (n=8). The median progression-free survival estimated according to Kaplan-Meier analysis was 12 months.</p><p><strong>Conclusion: </strong>The preliminary results of this study suggest that [<sup>225</sup>Ac]Ac-DOTATATE is stable, safe, and effective for treating advanced and [<sup>177</sup>Lu] Lu-DOTATATE-refractory NETs. However, prospective studies are needed to determine the impact of treatment on overall survival and to uncover potential side effects.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"32 3","pages":"226-232"},"PeriodicalIF":0.9,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fe/5c/MIRT-32-226.PMC10600558.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49692974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of Oxidized Regenerated Cellulose in Patients with Lung Cancer: A Biomaterial to Handle with Caution! 氧化再生纤维素在癌症患者中的应用:小心处理的生物材料!
IF 0.9
Molecular Imaging and Radionuclide Therapy Pub Date : 2023-10-20 DOI: 10.4274/mirt.galenos.2023.06641
Gianluca Franceschini
{"title":"Use of Oxidized Regenerated Cellulose in Patients with Lung Cancer: A Biomaterial to Handle with Caution!","authors":"Gianluca Franceschini","doi":"10.4274/mirt.galenos.2023.06641","DOIUrl":"10.4274/mirt.galenos.2023.06641","url":null,"abstract":"","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"32 3","pages":"255-256"},"PeriodicalIF":0.9,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/ad/MIRT-32-255.PMC10600556.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49692981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Study of CT-derived Radiation Dose Calculation in Lung Q-SPECT/CT Imaging. 肺Q-SPECT/CT成像中CT衍生辐射剂量计算的研究
IF 0.9
Molecular Imaging and Radionuclide Therapy Pub Date : 2023-10-20 DOI: 10.4274/mirt.galenos.2023.55707
Güler Silov, Fatih Boğa
{"title":"A Study of CT-derived Radiation Dose Calculation in Lung Q-SPECT/CT Imaging.","authors":"Güler Silov,&nbsp;Fatih Boğa","doi":"10.4274/mirt.galenos.2023.55707","DOIUrl":"10.4274/mirt.galenos.2023.55707","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the amount of effective dose (ED) due to the computed tomography (CT) component of lung perfusion-single-photon emission computed tomography (Q-SPECT)/CT.</p><p><strong>Methods: </strong>In this single-center retrospective study, imaging data were collected from the clinic database for the period 2016-2022. The 327 patients identified were aged between 20 and 94 years. Tube voltage, tube current, pitch, gantry rotation time, volume CT dose index, and dose-length product (DLP) were recorded. The DLP was then converted to an ED using the conversion factors. The comparison of the ED between two groups was performed using the Mann-Whitney U non-parametric test.</p><p><strong>Results: </strong>ED (mean ± standard deviation, mSv) was 1.20±0.70 for the pulmonary embolism (PE) (-) and 1.54±1.04 for the PE (+) cases (p<0.05). It was observed that there was a 28% increase in the ED for the PE (+) cases. In addition, each of the PE (-) and PE (+) cases was divided into two groups according to the use of the computed tomography dose reduction (CTDR): without CTDR protocol group (non-CTDR) and with CTDR protocol group (CTDR). For those groups, ED were obtained as 0.87±0.72 and 1.55±0.47 for PE (-) cases (p<0.05); 1.56±1.17 and 1.49±0.54 for PE (+) cases (p>0.05) correspondingly. For a deeper understanding, ED was calculated for all three groups formed with different tube voltage values applied for the non-CTDR and CTDR groups.There was a 42% decrease in the ED for group 1 PE (+) compared to group 2 PE (+) (1.21±0.28, 2.07±0.91, p<0.05) and there was a 41% decrease in the ED for group 1 PE (-) compared to group 2 PE (-) cases (1.17±0.32, 1.97±0.65, p<0.05).</p><p><strong>Conclusion: </strong>It could be concluded that the effective DR protocol is the non-CTDR protocol for the PE (-) cases and the application of the tube voltage at the level of 100 kVp for the PE (+) cases.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"1 1","pages":"214-220"},"PeriodicalIF":0.9,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f1/1e/MIRT-32-214.PMC10600546.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45864713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alterations in 18F-FDG Uptake Patterns may Limit Cross-sectional Evaluation of Adrenal Adenomas Using Single 18F-FDG PET/CT Imaging. 18F-FDG摄取模式的改变可能限制使用单一18F-FDGPET/CT成像对肾上腺腺瘤的横断面评估。
IF 0.9
Molecular Imaging and Radionuclide Therapy Pub Date : 2023-10-20 DOI: 10.4274/mirt.galenos.2023.98216
Fatih Tamer, Ülkem Yararbaş
{"title":"Alterations in <sup>18</sup>F-FDG Uptake Patterns may Limit Cross-sectional Evaluation of Adrenal Adenomas Using Single <sup>18</sup>F-FDG PET/CT Imaging.","authors":"Fatih Tamer,&nbsp;Ülkem Yararbaş","doi":"10.4274/mirt.galenos.2023.98216","DOIUrl":"10.4274/mirt.galenos.2023.98216","url":null,"abstract":"<p><p>Adrenal adenomas are observed in up to 7% of the population and are predominantly non-functional, increased <sup>18</sup>F-fluorodeoxyglucose (FDG) uptake is seen in only a small portion of them on <sup>18</sup>F-FDG positron emission tomography/computed tomography (PET/CT) imaging. In this report, we present the sequential <sup>18</sup>F-FDG PET/CT imaging findings of 2 patients with radiologically or pathologically confirmed adrenal adenomas who had severely altered <sup>18</sup>F-FDG uptake patterns in adrenal lesions in different imaging studies of the same patient. In light of these findings, we wanted to highlight that evaluating adrenal adenomas as cross-sectional with semi-quantitative PET/CT parameters obtained from single imaging may cause misinterpretation.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"32 3","pages":"247-249"},"PeriodicalIF":0.9,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fb/1e/MIRT-32-247.PMC10600554.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49692965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PET/CT Imaging of Inflammatory Myofibroblastic Tumor of the Thigh. 大腿炎性肌纤维母细胞瘤的PET/CT成像。
IF 0.9
Molecular Imaging and Radionuclide Therapy Pub Date : 2023-10-20 DOI: 10.4274/mirt.galenos.2023.55798
Refia Yükseltürk, Aslıhan Yıldırım, Nedim C M Gülaldı
{"title":"PET/CT Imaging of Inflammatory Myofibroblastic Tumor of the Thigh.","authors":"Refia Yükseltürk,&nbsp;Aslıhan Yıldırım,&nbsp;Nedim C M Gülaldı","doi":"10.4274/mirt.galenos.2023.55798","DOIUrl":"10.4274/mirt.galenos.2023.55798","url":null,"abstract":"<p><p>A 13-year-old male patient presented with right leg pain and walking difficulty. Contrast-enhanced magnetic resonance imaging showed a softtissue lesion between muscle groups in the anterior half of the right thigh. The excisional biopsy result ended in an inflammatory myofibroblastic tumor (IMT). The <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) scan showed hypermetabolism in the multifocal soft tissue lesion and also confirmed that no other distant foci were present. A three-phase Tc-99m-methylene diphosphonate study of the region showed heterogeneously increased vascularity within the region. We described an unusual case of IMT in a pediatric patient and the importance of PET/CT scanning to delineate the lesion.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"32 3","pages":"239-243"},"PeriodicalIF":0.9,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/10/MIRT-32-239.PMC10600557.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49692978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidental Detection of Sarcomatoid Lung Cancer by [18F] Choline Positron Emission Tomography/Computed Tomography. [18F]胆碱正电子发射断层扫描/计算机断层扫描对癌症肉瘤样肺的附带检测。
IF 0.9
Molecular Imaging and Radionuclide Therapy Pub Date : 2023-10-20 DOI: 10.4274/mirt.galenos.2023.81594
Rensi Marco, Decio Capobianco, Di Gregorio Fernando, Laura Evangelista
{"title":"Incidental Detection of Sarcomatoid Lung Cancer by [<sup>18</sup>F] Choline Positron Emission Tomography/Computed Tomography.","authors":"Rensi Marco,&nbsp;Decio Capobianco,&nbsp;Di Gregorio Fernando,&nbsp;Laura Evangelista","doi":"10.4274/mirt.galenos.2023.81594","DOIUrl":"10.4274/mirt.galenos.2023.81594","url":null,"abstract":"<p><p>A 79-year-old man treated for prostate cancer (PCa) in 2018 with concurrent hormone therapy and radical radiotherapy (RT) was given metastasis-directed RT because of skeletal progression of PCa in 2021. On [<sup>18</sup>F]-choline positron emission tomography/computed tomography (CT) for biochemical recurrence (prostate-specific antigen level: 4.96 ng/mL), he showed significant uptake in multiple skeletal lesions and focal uptake in a left lung nodule. CT-guided biopsy revealed a sarcomatoid lung carcinoma. This case confirms that histopathological evaluation is mandatory in the event of significant radiolabeled choline uptake in a single lung nodule.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"32 3","pages":"250-251"},"PeriodicalIF":0.9,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/98/12/MIRT-32-250.PMC10600544.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49692973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship Between Metabolic Activity, Cellularity, Histopathological Features of Primary Tumors and Distant Metastatic Potential in Breast Cancer. 癌症原发性肿瘤的代谢活性、细胞性、组织病理学特征与远处转移潜能的关系。
IF 0.9
Molecular Imaging and Radionuclide Therapy Pub Date : 2023-10-20 DOI: 10.4274/mirt.galenos.2022.60024
Uğuray Aydos, Seda Gülbahar Ateş, Osman Kurukahvecioğlu, Ümit Özgür Akdemir, Pınar Uyar Göçün, Lütfiye Özlem Atay
{"title":"Relationship Between Metabolic Activity, Cellularity, Histopathological Features of Primary Tumors and Distant Metastatic Potential in Breast Cancer.","authors":"Uğuray Aydos,&nbsp;Seda Gülbahar Ateş,&nbsp;Osman Kurukahvecioğlu,&nbsp;Ümit Özgür Akdemir,&nbsp;Pınar Uyar Göçün,&nbsp;Lütfiye Özlem Atay","doi":"10.4274/mirt.galenos.2022.60024","DOIUrl":"10.4274/mirt.galenos.2022.60024","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this study was to evaluate the relationship between the types of distant metastatic spread, histopathological features, and imaging features of primary tumor on positron emission tomography/magnetic resonance imaging (PET/MRI) for primary staging in newly diagnosed breast invasive ductal carcinoma (IDC) patients.</p><p><strong>Methods: </strong>Data from 289 female patients were retrospectively evaluated. Maximum standardized uptake value, metabolic tumor volume (MTV), total lesion glycolysis (TLG), and minimum apparent diffusion coefficient (ADC<sub>min</sub>) values of primary tumors were obtained from PET/MRI. The patients were grouped as non-metastatic, oligometastatic (1-5 metastatic lesions) and multimetastatic (>5 metastatic lesions) disease according to the number of distant metastases, and divided into two groups as isolated bone metastasis (IBM) and mixed/soft tissue metastasis (M-SM) groups according to the sites of metastatic spread.</p><p><strong>Results: </strong>Metabolic parameters had higher values and ADC<sub>min</sub> had lower values in the multimetastatic and oligometastatic groups than in the non-metastatic group. MTV was the only parameter that showed significant difference between the multimetastatic and oligometastatic groups. MTV and TLG were significantly higher in the M-SM group than in the IBM group. <sup>18</sup>F-fluorodeoxyglucose PET parameters had significantly higher values in grade 3, hormone receptor negative, human epidermal growth factor receptor 2 positive, triple negative, and highly proliferative (Ki-67 ≥14%) tumors. The prediction models that included imaging parameters to predict the presence of distant metastasis had higher discriminatory powers than the prediction models that included only histopathological parameters.</p><p><strong>Conclusion: </strong>Primary tumors with higher metabolic-glycolytic activity and higher cellularity were more aggressive and had higher metastatic potential in breast IDC. Compared with histopathological parameters alone, the combination of imaging parameters and histopathological features of primary tumors may help to better understand tumor biology and behavior.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"32 3","pages":"195-205"},"PeriodicalIF":0.9,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/17/MIRT-32-195.PMC10600550.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49692980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigation of Clinical Histopathologic Features and Metabolic Parameters of 18F-FDG PET/CT in Invasive Breast Carcinoma with a Micropapillary Component. 18F-FDG PET/CT在具有微乳头成分的浸润性乳腺癌中的临床组织病理学特征和代谢参数研究。
IF 0.9
Molecular Imaging and Radionuclide Therapy Pub Date : 2023-10-20 DOI: 10.4274/mirt.galenos.2023.06078
Elife Akgün, Göksel Alçın, Esra Canan Kelten Talu, Tevfik Fikret Çermik, Tuçe Söylemez Akkurt, Ebru Şen, Esra Arslan
{"title":"Investigation of Clinical Histopathologic Features and Metabolic Parameters of <sup>18</sup>F-FDG PET/CT in Invasive Breast Carcinoma with a Micropapillary Component.","authors":"Elife Akgün,&nbsp;Göksel Alçın,&nbsp;Esra Canan Kelten Talu,&nbsp;Tevfik Fikret Çermik,&nbsp;Tuçe Söylemez Akkurt,&nbsp;Ebru Şen,&nbsp;Esra Arslan","doi":"10.4274/mirt.galenos.2023.06078","DOIUrl":"10.4274/mirt.galenos.2023.06078","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this study was to evaluate the correlation between clinical histopathologic features and micropapillary (MP) ratio with the maximum standardized uptake value (SUV<sub>max</sub>) derived from <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) in treatment naïve breast cancer.</p><p><strong>Methods: </strong>Twenty-nine patients diagnosed with breast cancer with a MP component who underwent PET/CT imaging before any local and/or systemic treatment were included in this retrospective study. All clinical histopathological features were recorded. SUV<sub>max</sub> values were measured from <sup>18</sup>F-FDG PET images for primary tumors and metastatic axillary lymph nodes.</p><p><strong>Results: </strong>MP component percentage did not correlate with any clinical histopathological features except age. At early ages, the MP component ratio was significantly higher. Our results showed that there is no significant correlation between the SUV<sub>max</sub> value and MP component percentage.</p><p><strong>Conclusion: </strong>A high SUV<sub>max</sub> value is generally expected in aggressive malignancies. However, this assumption may not be valid for the MP subgroup, which has an aggressive course compared to other subgroups in breast cancer.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"32 3","pages":"221-225"},"PeriodicalIF":0.9,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/45/d4/MIRT-32-221.PMC10600551.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49692975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信